FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2732-2733 June 28, 2007 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Louik, C. Related Article by Alwan, S.

In the fall of 2005, GlaxoSmithKline called attention to recently collected safety data indicating an increased risk of major congenital malformations among infants exposed during organogenesis to GlaxoSmithKline's selective serotonin reuptake inhibitor (SSRI), paroxetine. Among 527 fetuses exposed to paroxetine in the first trimester, 23 were born with major congenital malformations. Most of the malformations were cardiovascular, and the majority of those were ventricular septal defects. As compared with infants born to women taking any other antidepressant agent during the first trimester, the adjusted odds ratio for any malformation was 2.2 (95% confidence interval [CI], 1.3 to 3.6). Previously published . . . [Full Text of this Article]

Source Information

From the Division of Maternal–Fetal Medicine, Massachusetts General Hospital, Boston.

This article has been cited by other articles:

• Wisner, K. L., Sit, D. K.Y., Hanusa, B. H., Moses-Kolko, E. L., Bogen, D. L., Hunker, D. F., Perel, J. M., Jones-Ivy, S., Bodnar, L. M., Singer, L. T. (2009). Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes. Focus 7: 374-384 [Abstract] [Full Text]  
• Wisner, K. L., Sit, D. K.Y., Hanusa, B. H., Moses-Kolko, E. L., Bogen, D. L., Hunker, D. F., Perel, J. M., Jones-Ivy, S., Bodnar, L. M., Singer, L. T. (2009). Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes. Am. J. Psychiatry 166: 557-566 [Abstract] [Full Text]  
• Yonkers, K. A. (2009). Parsing Risk for the Use of Selective Serotonin Reuptake Inhibitors in Pregnancy. Am. J. Psychiatry 166: 268-270 [Full Text]  
• Viguera, A. C., Emmerich, A. D., Cohen, L. S. (2008). Case 24-2008 -- A 35-Year-Old Woman with Postpartum Confusion, Agitation, and Delusions. NEJM 359: 509-515 [Full Text]  
• Kitzmiller, J. L., Block, J. M., Brown, F. M., Catalano, P. M., Conway, D. L., Coustan, D. R., Gunderson, E. P., Herman, W. H., Hoffman, L. D., Inturrisi, M., Jovanovic, L. B., Kjos, S. I., Knopp, R. H., Montoro, M. N., Ogata, E. S., Paramsothy, P., Reader, D. M., Rosenn, B. M., Thomas, A. M., Kirkman, M. S. (2008). Managing Preexisting Diabetes for Pregnancy: Summary of evidence and consensus recommendations for care. Diabetes Care 31: 1060-1079 [Full Text]  
• Yonkers, K. A. (2007). The Treatment of Women Suffering From Depression Who Are Either Pregnant or Breastfeeding. Am. J. Psychiatry 164: 1457-1459 [Full Text]  
• (2007). SSRIs in First-Trimester Pregnancy: Small Risks to the Fetus. JWatch Psychiatry 2007: 1-1 [Full Text]  
• (2007). SSRIs and Birth Defects -- How Concerned Should Our Patients Be?. JWatch Women's Health 2007: 1-1 [Full Text]  
• (2007). Do SSRIs Cause Birth Defects?. JWatch General 2007: 1-1 [Full Text]